Selective side-chain modification of cysteine and arginine residues blocks pathogenic activity of HIV-1-Tat functional peptides

Peptides

Volumn 27, Issue 4, 2006, Pages 611-621

  Devadas, Krishnakumar ^a   Boykins, Robert A ^a   Hardegen, Neil J ^b   Philp, Deborah ^b   Kleinman, Hynda K ^b   Osa, Etin Osa ^a   Wang, Jiun ^c   Clouse, Kathleen A ^c   Wahl, Larry M ^b   Hewlett, Indira K ^a   Rappaport, Jay ^d   Yamada, Kenneth M ^b   Dhawan, Subhash ^a  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^b NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

^c CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^d TEMPLE UNIVERSITY   (United States)

Author keywords

AIDS; HIV Tat; Peptides; Vaccination

Indexed keywords

ARGININE; CHEMOKINE RECEPTOR CCR5; CYSTEINE; GUANIDINE DERIVATIVE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; METHYL GROUP; PROTEIN ANTIBODY; THIOL DERIVATIVE; TRANSACTIVATOR PROTEIN;

ANGIOGENESIS; ARTICLE; CELL MIGRATION; CHEMICAL MODIFICATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SARCOMA CELL; VIRUS REPLICATION;

ARGININE; CELL LINE; CELL LINE, TUMOR; CYSTEINE; DNA REPLICATION; ENZYME ACTIVATION; GENE PRODUCTS, TAT; HIV INFECTIONS; HIV-1; HUMANS; MOLECULAR STRUCTURE; NEOVASCULARIZATION, PATHOLOGIC; NF-KAPPA B; PEPTIDE FRAGMENTS; RECEPTORS, CCR5; RECOMBINANT PROTEINS;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 33645406068     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.peptides.2005.09.013     Document Type: Article

References (56)

1. S.M. Agwale, M.T. Shata, M.S. Reitz, V.S. Kalyanaraman, R.C. Gallo, and M. Popovic A Tat subunit vaccine confers protective immunity against the immune-modulating activity of the human immunodeficiency virus type-1 Tat protein in mice Proc Natl Acad Sci 99 2002 10037 10041
2. A. Albini, R. Benelli, D. Giunciuglio, T. Cai, G. Mariani, and S. Ferrini Identification of a novel domain of HIV Tat involved in monocyte chemotaxis J Biol Chem 273 1998 15895 15900
3. A. Albini, R. Soldi, D. Giunciuglio, E. Giraudo, R. Benelli, and L. Primo The angiogenesis induced by HIV-1 tat protein is mediated by the Flk-1/KDR receptor on vascular endothelial cells Nat Med 2 1996 1371 1375
4. A. Albini, G. Barillari, R. Benelli, R.C. Gallo, and B. Ensoli Angiogenic properties of human immunodeficiency virus type 1 Tat protein Proc Natl Acad Sci 92 1995 4838 4842
5. G. Alkhatib, C. Combadiere, C.C. Broder, Y. Feng, P.E. Kennedy, and P.M. Murphy CC CKR5: a RANTES, MIP-1alpha. MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1 Science 272 1996 1955 1958
6. H. Asou, J.W. Said, R. Yang, R. Munker, D.J. Park, and N. Kamada Mechanisms of growth control of Kaposi's sarcoma-associated herpes virus-associated primary effusion lymphoma cells Blood 91 1998 2475 2481
7. A. Badou, Y. Bennasser, M. Moreau, C. Leclerc, M. Benkirane, and E. Bahraoui Tat protein of human immunodeficiency virus type1 induces interleukin-10 in human peripheral blood monocytes: implication of protein kinase C-dependent pathway J Virol 74 2000 10551 10562
8. G. Barillari, and B. Ensoli Angiogenic effects of extracellular human immunodeficiency virus type 1 Tat protein and its role in the pathogenesis of AIDS-associated Kaposi's sarcoma Clin Microbiol Rev 15 2002 310 326
9. G. Barillari, C. Sgadari, V. Fiorelli, F. Samaniego, S. Colombini, and V. Manzari The Tat protein of human immunodeficiency virus type-1 promotes vascular cell growth and locomotion by engaging the α5β1 and αvβ3 integrins and by mobilizing sequestered basic fibroblast growth factor Blood 94 1999 663 672
10. 3 integrin J Immunol 163 1999 1929 1935
11. R. Benelli, A. Barbero, S. Ferrini, P. Scapini, M. Cassatella, and F. Bussolino Human immunodeficiency virus transactivator protein (Tat) stimulates chemotaxis, calcium mobilization, and activation of human polymorphonuclear leukocytes: implications for Tat-mediated pathogenesis J Infect Dis 182 2000 1643 1651
12. C.A. Bohan, F. Kashanchi, B. Ensoli, L. Buonaguro, K. Boris-Lawrie, and J.N. Brady Analysis of Tat transactivation of human immunodeficiency virus transcription in vitro Gene Expression 2 1992 391 407
13. R.A. Boykins, J.A. Ardans, L.M. Wahl, R.B. Lal, K.M. Yamada, and S. Dhawan Immunization with a novel HIV-1-Tat multiple-peptide conjugate induces effective immune response in mice Peptides 21 2000 1839 1847
14. R.A. Boykins, M. Joshi, C. Syin, S. Dhawan, and H. Nakhasi Synthesis and construction of a novel multiple peptide conjugate system: strategy for a subunit vaccine design Peptides 21 2000 9 17
15. R.A. Boykins, R. Mahieux, U.T. Shankavaram, Y.S. Gho, S.F. Lee, and I.K. Hewlett Cutting edge: a short polypeptide domain of HIV-1-Tat protein mediates pathogenesis J Immunol 163 1999 15 20
16. L. Buonaguro, G. Barillari, H.K. Chang, C.A. Bohan, V. Kao, and R. Morgan Effects of the human immunodeficiency virus type 1 Tat protein on the expression of inflammatory cytokines J Virol 66 1992 7159 7167
17. A.I. Dayton, J.G. Sodroski, C.A. Rosen, W.C. Goh, and W.A. Haseltine The trans-activator gene of human T cell lymphotropic virus type III is required for replication Cell 44 1986 941 947
18. L. Del Sorbo, M. Arese, E. Giraudo, M. Tizzani, L. Biancone, and F. Bussolino Tat-induced platelet-activating factor synthesis contributes to the angiogenic effect of HIV-1 Tat Eur J Immunol 31 2001 376 383
19. F. Demarchi, F. d'Adda di Fagagna, A. Falaschi, and M. Giacca Activation of transcription factor NF-kappa B by the Tat protein of human immunodeficiency virus type 1 J Virol 70 1996 4427 4437
20. K. Devadas, and S. Dhawan Human immunodeficiency virus type-1 (HIV-1) Tat protein: mechanisms for activation of host factors and viral pathogenesis Recent Res Dev Biochem 4 2003 447 466
21. S. Dhawan, R.K. Puri, A. Kumar, H. Duplan, J.M. Masson, and B.B. Aggarwal Human immunodeficiency virus-1-Tat protein induces the cell surface expression of endothelial leukocyte adhesion molecule-1, vascular cell adhesion molecule-1, and intercellular adhesion molecule-1 in human endothelial cells Blood 90 1997 1535 1544
22. S. Dhawan, A. Heredia, L.M. Wahl, J.S. Epstein, M.S. Meltzer, and I.K. Hewlett Interferon-gamma-induced downregulation of CD4 inhibits the entry of human immunodeficiency virus type-1 in primary monocytes Pathobiology 63 1995 93 99
23. B. Ensoli, L. Buonaguro, G. Barillari, V. Fiorelli, R. Gendelman, and R.A. Morgan Release, uptake, and effects of extracellular human immunodeficiency virus type 1 Tat protein on cell growth and viral transactivation J Virol 67 1993 277 287
24. B. Ensoli, G. Aarillari, S.Z. Salahuddin, R.C. Gallo, and F. Wong-Staal Tat protein of HIV-1 stimulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patients Nature 345 1990 84 86
25. E. Fanales-Belasio, A. Carafo, A. Cara, Negri DRM, V. Fiorelli, and S. Butto HIV-1 Tat-based vaccines: from basic science to clinical trials DNA Cell Biol 21 2002 599 610
26. T.M. Folks, J. Justement, A. Kinter, C.A. Dinarello, and A.S. Fauci Cytokine-induced expression of HIV-1 in a chronically infected promonocytic cell line Science 238 1987 800 802
27. R.K. Ganju, N. Munshi, B.C. Nair, Z. Liu, P. Gill, and J.E. Groopman Human immunodeficiency virus Tat modulates the Flk-1/KDR receptor, mitogen-activated protein kinases, and components of focal adhesion in Kaposi's sarcoma cells J Virol 72 1998 6131 6137
28. L. Huang, I. Bosch, W. Hofmann, J. Sodoroski, and A.B. Pardee Tat protein induces human immunodeficiency virus type 1 (HIV-1) coreceptors and promotes infection with both macrophage-tropic and T-lymphotropic HIV-1 strains J Virol 72 1998 8952 8960
29. E. Izmailova, F.M.N. Bertley, Q. Huang, N. Makori, C.J. Miller, and R.A. Young HIV-1 Tat reprograms immature dendritic cells to express chemoattractants for activated T cells and macrophages Nat Med 9 2003 191 197
30. A. Kumar, S.K. Manna, S. Dhawan, and B.B. Aggarwal HIV-Tat protein activates c-Jun N-terminal kinases and activator protein-1 J Immunol 161 1998 776 781
31. R.M. Lafrenie, L.M. Wahl, J.S. Epstein, I.K. Hewlett, K.M. Yamada, and S. Dhawan HIV-1-Tat protein promotes chemotaxis and invasive behavior by monocytes J Immunol 157 1996 974 977
32. R.M. Lafrenie, L.M. Wahl, J.S. Epstein, I.K. Hewlett, K.M. Yamada, and S. Dhawan HIV-1 Tat modulates the function of monocytes and alters their interactions with microvessel endothelial cells J Immunol 156 1996 1638 1645
33. R.M. Lafrenie, L.M. Wahl, J.S. Epstein, K.M. Yamada, and S. Dhawan Activation of monocytes by HIV-Tat treatment is mediated by cytokine expression J Immunol 159 1997 4077 4083
34. S. Mitola, R. Soldi, I. Zanon, L. Barra, M.I. Gutierrez, and B. Berkhout Identification of specific molecular structures of human immunodeficiency virus type 1 Tat relevant for its biological effects on vascular endothelial cells J Virol 74 2000 344 353
35. A. Nath, K. Conant, P. Chen, C. Scott, and E.O. Major Transient exposure to HIV-1 Tat protein results in cytokine production in macrophages and astrocytes J Biol Chem 274 1999 17098 17102
36. D.M. Noonan, A. Gingeri, R. Meazza, O. Rosso, S. Mazza, and M. Muca-Perja Identification of immunodominant epitopes in inactivated Tat-vaccinated healthy and HIV-1-infected volunteers J Acq Immune Def Synd 33 2003 47 55
37. M. Ott, J.L. Lovett, L. Mueller, and E. Verdin Superinduction of IL-8 in T cells by HIV-1 Tat protein is mediated through NF-κB factors J Immunol 160 1998 2872 2880
38. M. Ott, S. Emiliani, C. Van Lint, G. Herbein, J. Lovett, and N. Chirmule Immune hyperactivation of HIV-1-infected T cells mediated by Tat and the CD28 pathway Science 275 1997 1481 1485
39. C.D. Partidos, E. Moreau, O. Chaloin, M. Tunis, J.P. Briand, and C. Desgranges A synthetic HIV-1 Tat protein breaches the skin barrier and elicits Tat-neutralizing antibodies and cellular immunity Eur J Immunol 34 2004 3723 3731
40. C.D. Pauza, P. Trivedi, M. Wallace, T.J. Ruckwardt, H. Le Buanec, and W. Lu Vaccination with Tat toxoid attenuates disease in simian/HIV-challenged macaques Proc Natl Acad Sci 97 2000 3515 3519
41. M.C. Poznansky, R. Foxall, A. Mhashikar, S. Coker, R. Jones, and U. Ramstead Inhibition of human immunodeficiency virus replication and growth advantage of CD4+ T cells from HIV-infected individuals that express intracellular antibodies against HIV-1 gp120 or Tat Hum Gene Ther 9 1998 487 496
42. H. Pu, J. Tian, G. Flora, Y.W. Lee, A. Nath, and B. Hennig HIV-1 Tat protein upregulates inflammatory mediators and induces monocyte invasion into the brain Mol Cell Neurosci 24 2003 224 237
43. L. Ramakrishna, K.K. Anand, K.M. Mohankumar, and U. Ranga Codon optimization of the Tat antigen of human immunodeficiency virus type-1 generates strong immune responses in mice following genetic immunization J Virol 78 2004 9174 9189
44. M.C. Re, G. Furlini, M. Vignoli, E. Ramazzotti, G. Zauli, and M. La Placa Antibody against human deficiency virus type 1 (HIV-1) Tat protein may have influenced the progression of AIDS in HIV-1-infected hemophiliac patients Clin Diagn Lab Immunol 3 1996 230 232
45. M.C. Re, M. Vignoli, G. Furlini, D. Gibellini, V. Colangeli, and F. Vitone Antibodies against full-length Tat protein and some low-molecular-weight Tat-peptides correlate with low or undetectable viral load in HIV-1 seropositive patients J Clin Virol 21 2001 81 89
46. M.W. Richardson, J. Mirchandani, J. Duong, S. Grimaldo, V. Kocieda, and H. Hendel Antibodies to Tat and Vpr in the GRIV cohort: differential association with maintenance of long-term non-progression status in HIV-1 infection Biomed Pharmacother 57 2003 4 14
47. M.W. Richardson, J. Mirchandani, P. Silvera, E.G. Regulier, C. Capini, and P.M. Bojczuk Immunogenicity of HIV-1 IIIB and SHIV 89.6P Tat and Tat toxoids in rhesus macaques: induction of humoral and cellular immune responses DNA Cell Biol 21 2002 637 651
48. A. Rubartelli, A. Poggi, R. Sitia, and M.R. Zocchi HIV-1 Tat: a polypeptide for all seasons Trends Immunol 19 1998 543 545
49. P. Silvera, M.W. Richardson, J. Greenhouse, J. Yalley-Ogunro, N. Shaw, and J. Mirchandani Outcome of simian-human immunodeficiency virus strain 89.6p challenge following vaccination of rhesus macaques with human immunodeficiency virus J Virol 76 2002 3800 3809
50. I. Tikhonov, T.J. Ruckwardt, G.S. Hatfield, and C.D. Pauza Tat-neutralizing antibodies in vaccinated macaques J Virol 77 2003 3157 3166
51. E. Toschi, G. Barillari, C. Sgadari, I. Bacigalupo, A. Creseto, and D. Carlei Activation of matrix-metalloproteinase-2 and membrane-type-1-matrix- metalloproteinase in endothelial cells and induction of vascular permeability in vivo by human immunodeficiency virus-1 Tat protein and basic fibroblast growth factor Mol Biol Cell 12 2001 2934 2946
52. L.M. Wahl, I.M. Katona, R.L. Wilder, C.C. Winter, B. Haraoui, and I. Scher Isolation of human mononuclear cell subsets by counterflow centrifugal elutriation (CCE). I. Characterization of B-lymphocyte-, T-lymphocyte-, and monocyte-enriched fractions by flow cytometric analysis Cell Immunol 85 1984 373 383
53. J.M. Weiss, A. Nath, E.O. Major, and J.W. Berman HIV-1 Tat induces monocyte chemoattractant protein-1-mediated monocyte transmigration across a model of the human blood-brain barrier and up-regulates CCR5 expression on human monocytes J Immunol 163 1999 2953 2959
54. R.F. Wu, Y. Gu, Y.C. Xu, S. Mitola, F. Bussolino, and L.S. Terada Human immunodeficiency virus type 1 Tat regulates endothelial cell actin cytoskeletal dynamics through PAK1 activation and oxidant production J Virol 78 2004 778 779
55. + cells by a tumor necrosis factor-related apoptosis-induced ligand-mediated mechanism J Virol 77 2003 6700 6708
56. V.S. Yedavalli, M. Benkirane, and K.T. Jeang Tat and trans-activation- responsive (TAR) RNA-independent induction of HIV-1 long terminal repeat by human and murine cyclin T1 requires Sp1 J Biol Chem 278 2003 6404 6410